Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

JTE-907

Selective inverse agonist of the CB2 receptor, a research reagent.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₄H₂₆N₂O₆

CAS 282089-49-0

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
438.50 g/mol

Updated on

In plain terms

JTE-907 is a laboratory molecule developed by a Japanese pharmaceutical group. It does not exist in hemp: it was designed to reduce the background activity of the CB2 receptor, one of the two receptors on which cannabinoids act, found mostly in tissues linked to the immune system. In mice, it reduced some inflammatory swellings of the skin; the data cited are preclinical.

Receptors and activity

Target network

CB2Inverse agonistKi = 0.4 nM · ratrat splenocytes; CB2/CB1 selectivity of 2 760 (cerebellar CB1)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to JTE-907: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of JTE-907.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Map sources

  1. Galiègue S et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem, 1995 (new tab)
  2. Ständer S et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005 (new tab)
  3. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
  4. Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)

Cited values

  1. CB2Inverse agonistKi = 35.9 nM · human57 out of 100

    Iwamura et al., J Pharmacol Exp Ther 2001 (new tab) · membranes of CHO cells expressing human CB2; CB2/CB1 selectivity of 66; increases forskolin-stimulated cAMP

  2. CB2Inverse agonistKi = 1.6 nM · mouse80 out of 100

    Iwamura et al., J Pharmacol Exp Ther 2001 (new tab) · membranes of CHO cells expressing mouse CB2; CB2/CB1 selectivity of 684

  3. CB2Inverse agonistKi = 0.4 nM · rat90 out of 100

    Iwamura et al., J Pharmacol Exp Ther 2001 (new tab) · rat splenocytes; CB2/CB1 selectivity of 2 760 (cerebellar CB1)

  4. CB1Binding (function not established)no measured value cited
  5. Unidentified pancreatic islet targetModulatorno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

JTE-907 is a selective inverse agonist of the CB2 receptor, developed by Japan Tobacco (Iwamura et al. 2001). Its affinities depend strongly on the species: Ki of 35.9 nM at human CB2, 1.55 nM at mouse CB2 and 0.38 nM at rat CB2, with selectivity ratios over CB1 of 66, 684 and 2,760. It increases forskolin-stimulated cAMP production in cells expressing CB2, the signature of an inverse agonist. In mice, given orally, it inhibited carrageenin-induced paw oedema (Iwamura et al. 2001), suppressed ear swelling induced by an ether analogue of 2-arachidonoylglycerol and, at 0.1-10 mg/kg, that induced by dinitrofluorobenzene (Ueda et al. 2005), and reduced all three phases of the ear swelling of an IgE-dependent skin reaction, which was absent in mice lacking CB2 (Ueda et al. 2007). This reading carries reservations: according to Salort et al. (2017), JTE-907 behaves as a « protean » ligand, its effect on the JNK protein in mouse brain reversing after repeated treatments; and it stimulates insulin secretion from human and mouse islets through a GPR55-independent mechanism (Ruz-Maldonado et al. 2021). All these data are preclinical.

Key sources.

History

Source
A synthetic molecule of the 2-oxoquinoline carboxamide class, developed by Japan Tobacco (Iwamura et al. 2001), absent from cannabis and from any living organism. A research reagent.

Origin

Research tool

No known biological pathway: a synthetic molecule of the 2-oxoquinoline carboxamide class, unrelated to the biosynthetic pathway of plant cannabinoids.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

JTE-907 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Iwamura H et al., In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor, J Pharmacol Exp Ther 2001 (new tab)PMID 11160626
  2. Raitio KH et al., Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists, J Med Chem 2006 (new tab)PMID 16539390
  3. Ueda Y et al., Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice, Eur J Pharmacol 2005 (new tab)PMID 16153638
  4. Ueda Y, Miyagawa N, Wakitani K, Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice, Life Sci 2007 (new tab)PMID 17055000
  5. Salort G, Álvaro-Bartolomé M, García-Sevilla JA, Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain, Psychopharmacology 2017 (new tab)PMID 28127623
  6. Ruz-Maldonado I et al., Direct Stimulatory Effects of the CB2 Ligand JTE 907 in Human and Mouse Islets, Cells 2021 (new tab)PMID 33809893
  7. ANSM, Consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV (new tab)
  8. PubChem, CID 9867770 (JTE-907) (new tab)

Identifiers

Names

IUPAC name
N-(1,3-benzodioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentoxy-1H-quinoline-3-carboxamide
Other names
JTE 907 · JTE907

Identifiers

Formula
C₂₄H₂₆N₂O₆
CAS
282089-49-0
PubChem CID
9867770(new tab)
InChIKey
GRAJFFFXJYFVOC-UHFFFAOYSA-N
SMILES
CCCCCOC1=C(C=CC2=C1NC(=O)C(=C2)C(=O)NCC3=CC4=C(C=C3)OCO4)OC

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.